World Congress on Breast Cancer, Birmingham, August 4 th 2015 Radio-immunotherapy of cancer Therapeutic efficacy, underlying mechanisms and potential applications.

Slides:

Advertisements

Similar presentations

October 23, 2014 John C. Lin, M.D. Ph.D. Vice President, Experimental Medicine Rational Combination of Immunotherapies in Preclinical Cancer Models.

Advertisements

Immunotherapy for Multiple Myeloma

Cancer immunology and immunotherapy. First an aside  Oncogenes and tumor suppressor genes.  Definitions anyone?  Oncogene –  Tumor suppressor gene.

Enhancement Of T-Cell Immunity To Osteosarcoma By Modulation Of Programmed Death Receptor Pathway Pooja Hingorani, Danielle Lussier, Joseph Blattman.

Immunology molecular medicine 3 Conleth Feighery.

Immunology 2 nd Med 2009 Some revision points Con Feighery.

Host Defense Against Tumors (Tumor Immunity)

Progress in Cancer Therapy Following Developments in Biopharma

Cancer immunotherapy: an update

Meredith Baker, MD PI: Bo Lu, MD – Radiation Oncology May 29th, 2014

Cancer immunotherapy: an update

Immunological tolerance and immune regulation -- 1

Objectives Introduction Ags expressed by cancer cells

Activation of T Lymphocytes

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

Tumor Immunity: Exploring the Role of a Checkpoint

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Adverse Renal Effects of Immune Checkpoint Inhibitors:

Jacques F.A.P. Miller, Michel Sadelain Cancer Cell

Immunological Tolerance

Discussion Outline Cells of the Immune System.

Tumor Immunology Ali Al Khader, MD Faculty of Medicine

Msc clinical immunology

Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers Ivana Catacchio, Anna Scattone, Nicola.

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Heating is a multifunctional adjuvant that affects tumor microenvironment through several intrinsic and extrinsic mechanisms, which could enhance immunotherapy.

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Schematic.

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Hiding in Plain Sight: How Cancer Evades the Immune System

Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC Stéphane Champiat, MD, Ecaterina Ileana, MD, Giuseppe Giaccone, MD, PhD, Benjamin.

Miki Ando, Hiromitsu Nakauchi Experimental Hematology

Figure 1 The role of CTLA4 and PD1 in T cell activation

Figure 2 Site of action of checkpoint inhibitors and agonists being

Mechanisms of immune escape in the tumor microenvironment.

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Mechanism of CTLA-4-induced immunosuppression.

Nat. Rev. Endocrinol. doi: /nrendo

Dendritic cells: regulators of hepatic immunity or tolerance?

Figure 1 Mechanisms of oncolytic-virus-based cancer therapy

Schematic representation of mechanisms leading to the synergy of anti-CD137 and anti–PD-1 immunostimulatory mAbs. Schematic representation of mechanisms.

Figure 1 Mechanisms of action of immunotherapy modalities

Tumor-Associated Macrophages: From Mechanisms to Therapy

Immunotherapy for Lung Cancer

Immunology Dr. Refif S. Al-Shawk

Shifting the Evolving CAR T Cell Platform into Higher Gear

Live and Let Die Immunity

Tumor Immunology Ali Al Khader, MD Faculty of Medicine

Cell-mediated immunity Regulation of the immune response

Mechanism of PD-1/PD-L1 pathway-induced immunosuppression within the tumour microenvironment. Mechanism of PD-1/PD-L1 pathway-induced immunosuppression.

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Releasing the Brakes on Cancer Immunotherapy

Padmanee Sharma, James P. Allison Cell

Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.

Dendritic-Cell-Based Therapeutic Cancer Vaccines

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

Potential models of how immune checkpoint blockade restores positive costimulation and modulates T-cell activity. Potential models of how immune checkpoint.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

BATF3-expressing professional antigen-presenting cells (DC) are able to cross-present tumor antigen (TA) by channeling material taken up from their environment.

Stable IL-10: A New Therapeutic that Promotes Tumor Immunity

Presentation transcript:

World Congress on Breast Cancer, Birmingham, August 4 th 2015 Radio-immunotherapy of cancer Therapeutic efficacy, underlying mechanisms and potential applications Paula Kroon, Nicole Haynes, Victoria Iglesias-Guimarais, Ricky Johnstone, Jules Gadiot, Marcel Verheij, Christian Blank, Jacques Neefjes, Jannie Borst, Inge Verbrugge

Curing metastatic cancer with systemic therapy Immunotherapy -Eliciting anti-tumor cytotoxic T cell responses (CTL) MHC I

Established tumors are poorly immunogenic Bottlenecks Lack of ‘foreign’ antigens –T cells do not recognize tumor cells Inhibition CTL activity by tumor / tumor micro-environment –PD-1 signaling –MHC I downregulation tumor cells Inspired by: Grosso JF et al. Can Immunity 2013;13:5-18

T cell-mediated immunotherapy; Signal (1) TCR triggering

TIL T cell Co-stimulatory receptor e.g. CD137 (4-1BB) Co-inhibitory receptor e.g. PD-1, CTLA-4 T cell-mediated immunotherapy; Signal (2) co-stimulation

Antibody-based immune-modulation Pembrolizumab Nivolumab Ipilimumab

Antibody-based immune-modulation

KILL

Problem: Immunotherapy as single-agent promising, but sub-optimal ‘Radio-immunotherapy’ Solution: Combine immunotherapy with radiotherapy

DNA damage 1.Reducing tumor cell clonogenicity -(Irreversible) cell cycle arrest -Mitotic catastrophe -Apoptosis Radiotherapy

DNA damage 1.Reducing tumor cell clonogenicity -(Irreversible) cell cycle arrest -Mitotic catastrophe -Apoptosis Radiotherapy 2.Immunomodulatory effects -Induce anti-tumor immune responses through release of tumor Ags -Upregulate MHCI

1) Efficacy? 2) Mechanism? 3) Potential applications?

Triple-negative breast cancer cell line Transplantable AT-3 breast cancer model (

Small animal Image-Guided Radiotherapy Movie: Jan-Jakob Sonke

Radiotherapy improves the response to immunotherapy Verbrugge I et al. Cancer Res 2012;72: Control Immunotherapy Radiotherapy Radio-immunotherapy

1) Efficacy? 2) Mechanism? 3) Potential applications?

Does it work? How does it work?

Verbrugge I et al. (2012) Cancer Research;72: IR+IT: radio-immunotherapy Start Tx: Day 14 n = 6 mice /group CD8+ T cells crucial for radio-immunotherapy

Does it work? How does it work?

Radiotherapy upregulates surface MHC I on AT-3 tumor cells Tumor Antigens (peptides) Radiotherapy

mTOR inhibition abrogates Radiotherapy-induced MHC I upregulation mTOR inhibitor Radiotherapy Verbrugge I et al. (2014) Radiation Research;182: Reits EA et al. (2006) J Exp Med; 203;

Importance of mTOR signaling to the therapeutic effect of radio-immunotherapy

Inhibition of mTOR signaling abrogates the therapeutic response to radio-immunotherapy Parentheses: fraction tumor-free mice at day 100 Verbrugge I et al. (2014) Radiation Research;182:

?? Radio-immunotherapy: summary and potential applications

Acknowledgements Netherlands Cancer Insitute (Amsterdam) Paula Kroon Jannie Borst Jacques Neefjes Victoria Iglesias Julia Walker Alessia Gasparini Javier Salguero Jan-Jakob Sonke Marcel Verheij Blank group Schumacher group De Visser group Clinicians PeterMac (Melbourne, Australia) Nicole Haynes Jim Hagekyriakou Mark Smyth Ricky Johnstone Juntendo University (Tokyo, Japan) Hideo Yagita (antibodies)